Reimbursed Care Access in Luxembourg

Currently classified as a strictly controlled substance under Luxembourg's primary drug law (Loi du 19 février 1973 and subsequent amendments) with no authorised medical use outside of approved clinical research. For public guidance Luxembourg's police/legal information and national drug legislation explicitly list “magic mushrooms (fungi)” among prohibited drugs and criminalise unauthorised possession, sale and production; there is no routine reimbursement or authorised clinical programme for psilocybin. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no framework for reimbursement of MDMA‑assisted therapy in Luxembourg outside of formal, regulatory‑approved trials. #

Esketamine (marketed as Spravato) holds a marketing authorisation across the EU (centralised EMA decision 18 December 2019) for adults with treatment‑resistant major depressive disorder, used in combination with an oral SSRI or SNRI; the EMA decision and product information describe restricted distribution and administration under supervised conditions due to risk of misuse and adverse effects. #

In Luxembourg esketamine falls under the same EU marketing authorisation framework and — like in other EU Member States — must be prescribed and administered under the special restricted‑prescription and supervised‑use conditions described by the EMA. Local implementation (including whether and how the national health insurance reimburses Spravato) is determined by national reimbursement and pricing procedures. Luxembourg’s health authorities manage control and oversight of prescription narcotics and related travel/certification processes for controlled medicines via the Direction de la Santé; clinicians in Luxembourg must follow the authorised product’s summary of product characteristics and national controlled‑substance rules when prescribing and administering esketamine. # #

Reimbursement note: Spravato’s EU authorisation enables national authorities to evaluate pricing and public reimbursement. At the time of writing there is no single EU‑wide reimbursement policy — Luxembourg’s reimbursement decision is handled via its national social insurance and pharmaceutical pricing/reimbursement pathways; clinicians or payers seeking the precise current reimbursement status (public social insurance coverage vs. private/self‑pay, billing codes, hospital pathways) should consult the Luxembourg national health reimbursement lists or contact the Division de la pharmacie et des médicaments (Direction de la Santé) and the CNS (Caisse Nationale de Santé) for an up‑to‑date determination and conditions for reimbursement. #

Ketamine (racemic) is an authorised medicinal anaesthetic across EU Member States (authorisations exist for injectable ketamine products) and remains an accepted medical product for anaesthesia and certain acute pain indications; this authorisation status means licensed ketamine products are available for legitimate medical use in Luxembourg under prescription and hospital supply channels. # #

Off‑label psychiatric use: across Europe there has been increasing off‑label use of ketamine for treatment‑resistant depression and other psychiatric indications administered in specialised clinic settings; such use is not an EMA‑authorised antidepressant indication, so any use for depression in Luxembourg would be off‑label and subject to local professional guidance, hospital formularies, and controlled‑substance regulations. Reimbursement for off‑label ketamine treatment for psychiatric indications is variable and typically limited: anaesthetic uses are covered as standard hospital medicines, whereas off‑label psychiatric infusion or clinic‑based programmes generally fall to hospital budgets or private payment unless a national payer authorises a specific reimbursement pathway. Clinicians and institutions must follow national controlled‑substance rules and local hospital/pharmacy formularies for procurement, documentation, and reporting. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no routine reimbursement pathway in Luxembourg for DMT products; access is limited to formal clinical trials with appropriate authorisations. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No public reimbursement or clinical programme exists in Luxembourg for 5‑MeO‑DMT; access is limited to approved research projects where permitted. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no authorised, reimbursed ibogaine treatment pathway in Luxembourg and use outside approved clinical trials would be unlawful. #

Currently classified as a strictly controlled substance under national drug scheduling laws (DMT content in ayahuasca is controlled); there is no authorised medical or reimbursed therapeutic use in Luxembourg outside of formal, approved clinical research. Possession, distribution or administration outside legal research frameworks is prohibited. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no reimbursement pathway for mescaline‑based therapy in Luxembourg. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 2C‑class phenethylamines (2C‑X) are unlawful to possess, supply or use outside of tightly regulated research settings. #